Patents Assigned to Abbott Biotechnology Ltd
  • Patent number: 7223394
    Abstract: Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor a (hTNF?) are disclosed. These antibodies have high affinity for hTNF? (e.g., Kd=10?8 M or less), a slow off rate for hTNF? dissociation (e.g., Koff=10?3 sec?1 or less) and neutralize hTNF? activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNF? and for inhibiting hTNF? activity, e.g., in a human subject suffering from a disorder in which hTNF? activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.
    Type: Grant
    Filed: March 7, 2001
    Date of Patent: May 29, 2007
    Assignee: Abbott Biotechnology Ltd
    Inventors: Jochen G. Salfeld, Deborah J. Allen, Hendricus R. J. M. Hoogenboom, Zehra Kaymakcalan, Boris Labkovsky, John A. Mankovich, Brian T. McGuinness, Andrew J. Roberts, Paul Sakorafas, David Schoenhaut, Tristan J. Vaughan, Michael White, Alison J. Wilton